US Stock MarketDetailed Quotes

MGRX Mangoceuticals

Watchlist

0.235
+0.007+3.16%

Close Sep 26 16:00 ET

0.242
+0.007+2.89%

Post 20:01 ET

7.03MMarket Cap-751P/E (TTM)

Mangoceuticals Stock Forum

JiuShini

Sep 25 08:52

$Mangoceuticals (MGRX.US)$ We are going to see 0.1 then delisting by next year?

NercZ24

Sep 24 08:07

$Mangoceuticals (MGRX.US)$
hmmm?

JiuShini

Sep 6 07:44

$Mangoceuticals (MGRX.US)$Mangoceuticals, Inc., a company listed in the United States, has achieved a significant milestone with the Securities and Exchange Commission (SEC). The SEC has declared the company's Form S-1 effective as of September 5, 2024, at 4:30 P.M. This form is typically used by companies to register new securities for sale to the public, indicating that Mangoceuticals may be preparing to offer new shares. The effectiveness of the form marks a crucial step in the process, allowi...

Jaguar8

Aug 30 16:30

S1 withdrawal

$Mangoceuticals (MGRX.US)$

71306807

Aug 15 10:39

$Mangoceuticals (MGRX.US)$
There must be some underlying issue stopping this from a considered reevaluation upwards .
Anything out there ?

Jaguar8

Aug 15 08:25

NEWS

$Mangoceuticals (MGRX.US)$
MangoRx Reports 1,685% Increase in Shareholders’ Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024
MangoRx (NASDAQ: MGRX) reported significant financial growth for the first half of 2024. The company's shareholders' equity surged by 1,685%to $13.8 million, largely due to the acquisition of a global patent portfolio for respiratory illness technology.
Gross revenues increased by 55.92% to $377,258, with gros...

Jaguar8

Aug 13 15:04

NEWS

$Mangoceuticals (MGRX.US)$
MangoRx Receives Certificate of Grant in India for its Respiratory Illness and Preventive Care Technology Patent
MangoRx (NASDAQ: MGRX) has received a Certificate of Grant in India for its respiratory illness and preventive care technology patent. The patent, valid until March 16, 2040, covers a proprietary formulation designed to combat infections including colds, respiratory diseases, and orally transmitted infections like HPV. This follows MangoRx's acquisition o...